Renovorx, Inc. · NASDAQ:RNXT
Renovorx — Q2 2026 Earnings Presentation
31 slides from Renovorx's earnings presentation, Aug 12, 2026
Slide 1: Investor Presentation
Investor Presentation NASDAQ | RNXT Delivering therapy where it matters® June 2026 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, i
Slide 3: RenovoRx at a Glance
RenovoRx at a Glance RenovoRx is a life-science company developing innovative targeted oncology therapies and is actively commercializing TAMP platform and patented, FDA-cleared RenovoCath Device for drug-delivery Advancing adoption of FDA-cleared RenovoCath® at U.S. Cancer Centers, strengthening co
Slide 4: Proprietary Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform
Proprietary Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform Enabled by RenovoCath 3 NASDAQ | RNXT
Slide 5: Addressing a Significant Problem in Cancer Treatment
Addressing a Significant Problem in Cancer Treatment Hypervascular tumors are inadequately treated with current Hypovascular tumors = major barrier to chemotherapy treatment therapies success For example, liver tumors are highly vascularized Many tumors, like pancreatic tumors, have poor blood suppl
Slide 6: TAMP Improves a Drug's Therapeutic Index
TAMP Improves a Drug’s Therapeutic Index Increases Drug Concentration to Reduces Drug AUC0-t by 43.5% Compared to IV Target Pathological Site by ~100X1 Administration2 Tissue Concentration Gem. (ng/g) Drug Exposure IA vs. IV route 10^6 15 Gemcitabine AUC0-t (h*mcg/mL) 10^5 10 10^4 10^3 5 10^2 0 10^1
Slide 7: Illustration of TAMP with RenovoCath
6 Illustration of TAMP with NASDAQ | RNXT RenovoCath
Slide 8: Mechanism: Trans-Arterial Micro-Perfusion (TAMP)
Mechanism: Trans-Arterial Micro-Perfusion (TAMP) Mechanism: after vessel isolation, increase in pressure forces drug across the artery wall into the micro-vasculature and into tissue At optimal pressure – tissue pressure is overcome, forcing delivery outside the 70 primary vessel into the tissue 60
Slide 9: Patient and Physician Experience
Patient and Physician Experience RenovoCath Other Treatment Options RenovoCath Patient Experience Other Patient Experience ▪ ~8 treatments over 4 months (2x/month hospital visits) with ▪ Traditional systemic gemcitabine + Abraxane: 12 hospital/clinic visits disposable device (no implant) over 4-mont
Slide 10: Physicians Have Expressed Interest in TAMP Platform and RenovoCath
Physicians Have Expressed Interest in TAMP Platform and RenovoCath for Drug-Delivery Across a Broad Market 200000 NEW ANNUAL CASES (U.S.) All Cases Cases with RenovoCath 160000 120000 80000 40000 0 PANCREATIC1 LAPC2 CCA3 eCCA4 LUNG NSCLC GLIOMA7 GLIOBLASTOMA8 Sarcomas11 UTERINE9 TACE ELIGIBLE (NSCLC
Slide 11: Commercial Opportunity: RenovoCath Standalone, FDA-Cleared Drug-Delivery Device
Commercial Opportunity RenovoCath Standalone, FDA-Cleared Drug-Delivery Device 10 NASDAQ | RNXT
Slide 12: High Margin, Large Market, Opportunity for RenovoCath Standalone Device
High Margin, Large Market, Opportunity for RenovoCath Standalone Device RenovoCath Market Opportunity Analogous pressure-mediated delivery $6k-$8.5k/unit1 catheter ASPs Annual average procedures 5-6 per patient2 Patented, Highly Defensible Position Initial peak U.S. potential revenue $400M3 RenovoRx
Slide 13: RenovoCath Go-to-Market Strategy
RenovoCath Go-to-Market Strategy 2025 Limited Market Launch (without recently established commercial team) Builds Foundation for 2026 Commercialization Ramp and Revenue Growth RenovoCath potential high-volume centers1 Go-To-Market Strategy • Broadening adoption momentum: Customer pipeline continues
Slide 14: RenovoCath Commercialization Update
RenovoCath Commercialization Update (as of 05/6/26) 2025 Commercial Exploration Laid Foundation for 2026 Revenue Growth and Commercialization RenovoCath customers actively treating patients: 16 cancer centers Pipeline expansion: 48 total centers have approximately quadrupled near-term RenovoCath Cus
Slide 15: Combination Product Pipeline & IIT Strategy
Combination Product Pipeline & IIT Strategy Centers can bill for the TAMP procedure regardless of the agent administered. To generate new data, RenovoRx supports Investigator-Initiated Studies (IITs) and are conducting a Phase III TIGeR-PaC trial exploring administration of a variety of agents. Drug
Slide 16: Pivotal Phase III TIGeR-PaC Clinical Trial in LAPC
Pivotal Phase III TIGeR-PaC Clinical Trial (NCT03257033) in Locally Advanced Pancreatic Cancer (LAPC) 15 NASDAQ | RNXT
Slide 17: Significant Unmet Need
Significant Unmet Need Three FDA approvals in the last 10 years showed minimal Median Overall Survival (OS) benefit and increased toxicity1 Gemcitabine + Abraxane Abraxane 38% Grade 3 Abraxane obtained FDA approval in 2013 on a or Higher Neutropenia and 7-week Median Overall Survival (OS) benefit2 1
Slide 18: Potential Market Penetration Based on Modest Efficacy from TIGeR-PaC
Potential Market Penetration Based on Modest Efficacy from TIGeR-PaC Independent interviews suggest oncologists likely to adopt gemcitabine delivered via RenovoCath w/ at least 3–4-month OS benefit and toxicity improvement are met 5 Number of Respondents 4 3 2 1 0 <1 1 month 2 months 3 months 4 mont
Slide 19: RR3 TIGeR-PaC Phase III Randomized Trial
RR3 TIGeR-PaC Phase III Randomized Trial Combination product trial for TAMP Delivery of Intra-Arterial (IA) Gemcitabine (IAG) via FDA-Cleared RenovoCath in Locally Advanced Pancreatic Cancer Induction Phase 1:1 RANDOMIZATION PHASE 1◦ Endpoint 4-Month treatment protocol: standard of care IV (systemic
Slide 20: Statistics and Trial Status
Statistics and Trial Status Incremental Significance Level Percent of Final Analysis Total Number of Observed Events (Deaths) to Interim Analysis at time of Events Trigger Analysis Interim Analysis First 30% 26 0.0001 Second 60% 52 0.008 Final 100% 86 0.048 Statistical Design Enrollment Status Pre-P
Slide 21: TAMP (IA gemcitabine): 6-month Median OS Benefit vs. IV gemcitabine + Abraxane
TAMP (IA gemcitabine): 6-month Median OS Benefit vs. IV (systemic) gemcitabine + Abraxane TIGeR-PaC phase III first interim analysis Data on 45 patients randomized INDUCTION RANDOMIZED TREATMENT & FOLLOW-UP s • 23 randomized to RenovoCath plus Gemcitabine • 22 randomized to IV gemcitabine + Abraxane
Slide 22: TAMP (IA Gem): Fewer AEs and SAEs vs IV gemcitabine + Abraxane
TAMP (IA Gem): Fewer AEs and SAEs vs IV (systemic) gemcitabine + Abraxane TIGeR-PaC phase III first interim analysis 65% fewer total AEs and SAEs Fewer AEs in 11/13 categories with greater than 10% frequency in IA vs. IV arm in each arm (All Grades) 300 Adverse Events IV Gem + Pac IA Gem Neutropenia
Slide 23: Post-Marketing Registry Study (RR5) & Support of Investigator-Initiated Trials
Post-Marketing Registry Study (RR5) & Support of Investigator-Initiated Trials (IITs) Evidence-Based Growth Strategy Clinical and Strategic Advancement Objective Participating Clinical Sites ▪ Expand safety and performance data of RenovoCath and its ▪ University of Vermont Cancer Center associated s
Slide 24: Financial Highlights
Financial Highlights Q1 2026 Revenue: $563K, 136% Over Q4 2025 Revenue RNXT (USD) Daily Performance - 2026 YTD through May 13 ▪ Fully staffed and experienced commercial team in place in 2026 to 1.20 YTD Close high of 1.16; drive revenue growth 1Q26 Close of 1.01 2026 intraday high of 1.10 $1.30 ▪ FY
Slide 25: Experienced Management Team
Experienced Management Team Shaun R. Bagai Richard Stark Chief Executive Officer & Board Member Commercial Advisor Consultant 2 ▪ HeartFlow (>$2B IPO) ▪ Innoblative Designs ▪ Ardian (Acquired for > $900M) ▪ AngioDynamics ▪ Medtronic Vascular ▪ TransVascular (Acquired by Medtronic) Ramtin Agah, MD Ro
Slide 26: Board of Directors
Board of Directors Ramtin Agah, MD Laurence J. Marton, MD Executive Chairman, Chief Medical Officer, & Founder Director ▪ Interventional Cardiology, El Camino Hospital ▪ Board: Cellsonics, TOMA Biosciences, xCures ▪ Consultant, Abbott Vascular Shaun R. Bagai Una S. Ryan, PhD, OBE Director & Chief Ex
Slide 27: Scientific Advisory Board
Scientific Advisory Board Timothy Donahue, MD Karyn A. Goodman, MD, MS ▪ Director of the UCLA Agi Hirshberg Center for Pancreatic ▪ Professor and Vice Chair of Clinical Research, Department of Diseases Radiation Oncology, Icahn School of Medicine at Mount Sinai ▪ Garry Shandling Chair in Pancreatic
Slide 28: RenovoCath Medical Advisory Board
RenovoCath Medical Advisory Board Nadine Abi-Jaoudeh, MD Mustafa Al-Roubaie, MD ▪ Chief of Interventional Radiology and Director of Clinical ▪ Interventional Radiologist at Moffitt Cancer Center Research in the Department of Radiology at the ▪ Associate Professor of Radiology and Oncologic Sciences
Slide 29: Upcoming Milestones
Upcoming Milestones 2026 2027 Q1 Q2 Q3 Q4 Q1 Q2 RenovoCath Generates Completion of $1.1 Million in 2025 TIGeR-PaC Revenue Trial Enrollment RenovoRxinReports First Full Final human PK Year of by June 2026 Q1-Q3 RenovoCath data supporting Commercialization Revenues of ~$900K with RenovoRx Named to Fas
Slide 30: How Hospitals are Using TAMP with RenovoCath in Oncology Management
How Hospitals are Using TAMP with RenovoCath in Oncology Management* Visit https://ir.renovorx.com/news-events/clinical-news to Learn More NBC News highlighted the potential of RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform, designed for targeted drug-delivery via the RenovoCath d
Slide 31: Thank You
Investor Relations Contact: Thank You KCSA Strategic Communications Valter Pinto or Jack Perkins | RenovoRx@KCSA.com +1.212.896.1254 Media Contact: StiR Communications Hannah Williams | Hannah@stir@communications.com +1.803.521.1214 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT